Amarin Corp Plc (AMRN)

[lettruthringout]

Speaking of off-label use


The prestigious North American researcher Deepak L. Bhatt, Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School, presented the primary results of the first trial called VASCEPA COVID-19 CardioLink-9 in humans of a loading dose of "icosapent ethyl" -compound present in Omega-3- in patients with the new coronavirus.


"I am very excited to present the first human trial of an ethyl loading dose of icosapent," Bhatt anticipated in the run-up to the big event. “If this approach is found to be safe and well tolerated, it could serve as a prelude to future trials of this drug using a loading dose at the time of a heart attack or stroke, as well as in patients undergoing urgent procedures such as a stenting and / or bypass surgery.

https://revistaenterate.com.ar/un-prestigioso-cardiologo-de-harvard-revelo-que-el-omega-3-podria-ser-un-posible-tratamiento-para-pacientes-leves-con-covid-19-por-sus-propiedades-antiinflamatorias/